Kynmobi Safe, Effective for ‘Off’ Periods Over Long Term, Ongoing Trial Reports
Sep 15, 2020 07:00 am | Marisa Wexler
Sunovion‘s Kynmobi (apomorphine hydrochloride), a sublingual film treatment for “off” episodes in people with Parkinson’s disease, has a manageable safety profile and maintains efficacy over up to nearly a year of use, interim data from an ongoing Phase 3 trial show. Findings were presented at MDS Virtual Congress 2020 in the study, “A Long-Term Safety, Tolerability, […]
The post Kynmobi Safe, Effective for ‘Off’ Periods Over Long Term, Ongoing Trial Reports appeared first on Parkinson's News Today.